BioSpace News Archive

Men initially diagnosed in later stages more likely to say prostate cancer has impacted sexual health, people don’t understand what they’re going through

A researcher from the University of Houston has created a form of recombinant insulin that could potentially address some of the biggest concerns about the lifesaving drug, including its price.

ASCO has hand selected PharmaMar’s (MSE:PHM) abstract 8906 for the “Best of ASCO” meetings in the summer over three US cities and 30 others over 5 continents.

The pivotal phase III study for Budesolv has provided Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, with clinical validation of the efficacy of its innovative Marinosolv® technology platform.

ALPHAEON Corporation announced that it has agreed to sell approximately 4.0 million shares of common stock in Evolus, Inc. in an underwritten public offering with Morgan Stanley acting as sole underwriter for the offering.

Hebron Technology Co., Ltd. announced its financial results for the fiscal year ended December 31, 2018.

MEI Pharma, Inc. announced the publication of data abstracts related to two of MEI Pharma’s clinical stage drug development programs to be presented at the 2019 ASCO Annual Meeting to be held May 31 to June 4, 2019 in Chicago.

Sanofi’s oncology franchise and robust pipeline will be featured at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, delivering against a renewed strategy to address difficult-to-treat and difficult-to-eradicate cancers, including certain types of multiple myeloma, skin cancer, breast cancer, and lung cancer.

Ogivri™ is the first biosimilar for Herceptin® approved by the U.S. Food and Drug Administration (FDA) for all indications including HER2-positive breast and gastric cancers [15-May-2019] HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , May 15, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced

ImmunoGen, Inc. announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin® in patients with folate receptor alpha-positive platinum-resistant ovarian cancer.